ClinicalTrials.gg
CompletedNCT01306721Updated Oct 16, 2013

Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis

A Phase 3 interventional study of fexofenadine HCL (M016455) and pseudoephedrine in Rhinitis Seasonal, sponsored by Sanofi. Completed at 3 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2013-10-16.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

Primary Objective:

  • To evaluate the efficacy on the nasal congestion of a twice-daily fexofenadine HCl 60 mg - pseudoephedrine HCl 60 mg combination (FEX60/PSE60) and fexofenadine HCl 60 mg - pseudoephedrine HCl 120 mg combination (FEX60/PSE120) versus fexofenadine HCl 60 mg (FEX60) in patients with seasonal allergic rhinitis (SAR).

Secondary Objectives:

  • To evaluate the efficacy of a twice-daily FEX60/PSE60 and FEX60/PSE120 versus FEX60 on nasal symptoms (sneezing, rhinorrhea, and nasal congestion), eye symptom, and daily activity impairment.
  • To assess the safety of a twice-daily FEX60/PSE60 and FEX60/PSE120 versus FEX60.
Read the detailed description

The study duration for each patient is 3 weeks and 3 days:

  1. Lead-in period: 1 week
  2. Treatment period: 2 weeks
  3. Follow-up period: 3 days
02

Conditions studied

  • Rhinitis Seasonal

Browse trials for

03

In context

Rhinitis

246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.

This study's enrollment of 520 is above the median of 80 across 187 interventional studies indexed under Rhinitis.

Browse Rhinitis studies →

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with seasonal allergic rhinitis (SAR): Patients with a history of SAR symptoms during the season when cedar pollen levels are increased for at least 2-years

Exclusion criteria

Exclusion criteria:

  • At the start of the placebo lead-in period:

    • Patients who are negative for IgE Antibody test
    • Expected nasal congestion score is less than 2
  • The last 3 days of the lead-in period:

    • Nasal congestion scores are 2 or more and not all 4
    • Patients with all nasal symptoms (sneezing, rhinorrhea, and nasal congestion). A total score for nasal symptoms (sneezing, rhinorrhea, and nasal congestion) and eye symptom is less than 6
    • Patients with 2 or more nasal symptoms (sneezing and rhinorrhea) and eye symptoms score is 4

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
520 participants (actual)

Study arms

  • Active comparator
    FEX 60 mg

    Study medications is administered one hour before or two hours after a meal twice a day. Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) Double-blind treatment period: 1 tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg /pseudoephedrine 60 mg (fixe dose combination)

    Drug: fexofenadine HCL (M016455) · Drug: pseudoephedrine · Drug: fexofenadine HCL matching placebo · Drug: pseudoephedrine matching placebo

  • Experimental
    FEX 60 mg/PSE 60 mg

    Study medications is administered one hour before or two hours after a meal twice a day. Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination Double-blind treatment period: 1 tablet of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 60 mg / pseudoephedrine 60 mg (fixe dose combination)

    Drug: fexofenadine HCL (M016455) · Drug: pseudoephedrine · Drug: fexofenadine HCL matching placebo · Drug: pseudoephedrine matching placebo

  • Experimental
    FEX 60 mg/PSE 120 mg

    Study medications is administered one hour before or two hours after a meal twice a day. Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) Double-blind treatment period: 2 tablets of fexofenadine 30 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 30 mg

    Drug: fexofenadine HCL (M016455) · Drug: pseudoephedrine · Drug: fexofenadine HCL matching placebo

Interventions

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

  • Drugfexofenadine HCL matching placebo

    Pharmaceutical form:tablet Route of administration: oral

  • Drugpseudoephedrine matching placebo

    Pharmaceutical form:tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Changes in the nasal congestion score based on the patient's symptom diary

    Time frame: over 2 treatment weeks (from baseline to end of treatment)

Secondary outcomes

  1. Changes in the total score of 4 symptoms, each nasal symptom (sneezing, rhinorrhea, and nasal congestion) and eye symptom

    Time frame: over 2 treatment weeks (from baseline to end of treatment)

  2. Changes in total score of 4 symptoms on a daily, day-time, and night-time bases

    Time frame: over 2 treatment weeks (from baseline to end of treatment)

  3. Changes in each symptom (sneezing, rhinorrhea, nasal congestion, and eye symptoms) score and the daily activity impairment score

    Time frame: over 2 treatment weeks (from baseline to end of treatment)

  4. Changes in each symptom score and the daily activity impairment score on a daily, day-time and night-time basis

    Time frame: over 2 treatment weeks (from baseline to end of treatment)

  5. Nasal findings

    Time frame: over 2 treatment weeks (from baseline to end of treatment)

  6. Patient's impression

    Time frame: over 2 treatment weeks (from baseline to end of treatment)

  7. Patient's safety

    Time frame: over 2 treatment weeks (from baseline to end of treatment)

07

Study locations

3 sites
  • Investigational Site Number 392002
    Koganei-Shi, Japan
  • Investigational Site Number 392003
    Osaka-Shi, Japan
  • Investigational Site Number 392001
    Shinjuku-Ku, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2011
First posted
Mar 2, 2011
Start
Feb 2011
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Last update
Oct 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01306721
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 2, 2011
Start date
Feb 2011
Primary completion
Apr 2011
Completion
Apr 2011
Last update
Oct 16, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fexofenadine · Pseudoephedrine

Start the discussion